

1. Record Nr.	UNINA9910765705803321
Titolo	AML in the molecular age : from biology to clinical management // edited by Celalettin Ustun, Lucy A. Godley
Pubbl/distr/stampa	Basel, Switzerland : , : MDPI, , [2018] ©2018
ISBN	3-03897-281-9
Descrizione fisica	1 online resource (196 pages)
Collana	Journal of clinical medicine
Disciplina	616.99/419
Soggetti	Acute myeloid leukemia
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	About the Special Issue Editors . vii -- Preface to "AML in the Molecular Age: From Biology to Clinical Management" ix -- Sophia Yohe Molecular Genetic Markers in Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 460-478, doi: 10.3390/jcm4030460 . 1 -- Gustavo M. Cervantes and Zuzan Cayci Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author's Institution Reprinted from: J. Clin. Med. 2015, 4, 1102-1112, doi: 10.3390/jcm4051102 . 16 -- Elzbieta Gocek and George P. Studzinski The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy Reprinted from: J. Clin. Med. 2015, 4, 504-534, doi: 10.3390/jcm4040504 . 25 -- Caroline Benedicte Nitter Engen, Line Wergeland, Jørn Skavland and Bjørn Tore Gjertsen Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions Reprinted from: J. Clin. Med. 2014, 3, 1466-1489, doi: 10.3390/jcm3041466 . 50 -- Marjan Cruijssen, Michael L "ubbert, Pierre Wijermans and Gerwin Huls Clinical Results of Hypomethylating Agents in AML Treatment Reprinted from: J. Clin. Med. 2015, 4, 1-17, doi: 10.3390/jcm4010001 . 69 -- Prithviraj Bose and Steven Grant Rational Combinations of Targeted Agents in AML Reprinted from: J. Clin. Med. 2015, 4, 634-664, doi: 10.3390/jcm4040634 . 83 -- Guldane Cengiz Seval and Muhit Ozcan Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult

Patients Reprinted from: J. Clin. Med. 2015, 4, 441-459, doi: 10.3390/jcm4030441 . 107 -- Jasmijn D. E. de Rooij, C. Michel Zwaan and Marry van den Heuvel-Eibrink Pediatric AML: From Biology to Clinical Management Reprinted from: J. Clin. Med. 2015, 4, 127-149, doi: 10.3390/jcm4010127 . 122 -- Gabriela Soriano Hobbs and Miguel-Angel Perales Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients Reprinted from: J. Clin. Med. 2015, 4, 488-503, doi: 10.3390/jcm4030488 . 140 -- Nelli Bejanyan, Housam Haddad and Claudio Brunstein Alternative Donor Transplantation for Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 1240-1268, doi: 10.3390/jcm4061240 . 152 -- Nestor R. Ramos, Clifton C. Mo, Judith E. Karp and Christopher S. Hourigan Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 665-695, doi: 10.3390/jcm4040665 . 174.

---

## Sommario/riassunto

In this Special Issue, we aim to discuss important scientific and clinical ongoing activities in AML. Scientific subjects will include articles concerning the molecular abnormalities, epigenetic mechanisms of disease/therapy as well as the role of the immune system in AML. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of AML and currently emerging and promising investigational therapies. Specifics of treatment of pediatric and younger patients with AML. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive AML, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e. g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With significant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described.

---